Tumor treating fields have demonstrated efficacy and safety, especially in glioblastoma treatment, but clinical uptake ...
The phase 1b/2 ELEVATE study evaluated everolimus, an mTORC1 inhibitor, plus elacestrant, a next-generation, oral selective ER degrader, in adult patients with ER+/HER2- breast cancer.
In this study, researchers developed and evaluated a blood-based cell-free and exosomal miRNA panel for detecting early-stage CRC and advanced adenomas.
Researchers evaluated the real-world outcomes of lisocabtagene maraleucel in patients with relapsed or refractory large B-cell lymphoma.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results